Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases

NEXT STORY
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
PREV STORY
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Decisions taken by Orion Corporation’s Annual General Meeting on 25 March 2021

author_avatar
NASDAQ Market News

United States Companion Animal Diagnostics Market Outlook and Forecast 2018-2023: Growing Demand for Automated Analyzers and Integration of Various Diagnostic Platforms

author_avatar
NASDAQ Market News

Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events

Bagsværd, Denmark, 27 July 2017 - The European Commission has approved an update to ...

author_avatar
NASDAQ Market News